Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immunome Inc.IMNM · Entity 4219 | Director | August 10, 2026 | August 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immunome Inc.
Report date August 10, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Last balance in matching sequence
After 2026-08-11 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-08-10 · Sale · Disposed 10,125 · Balance 62,291 F1: The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC ("ABHMC") on March 31, 2026. F2: The weighted average sale price for the transaction report was $26.07, and the range of prices were between $26.005 and $26.14, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3: ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares. Row 2 · 2026-08-11 · Sale · Disposed 62,291 · Balance 0 F1: The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC ("ABHMC") on March 31, 2026. F4: The weighted average sale price for the transaction report was $26.23, and the range of prices were between $26.00 and $26.48, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3: ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares. |
| Common StockSEC Table I · non-derivative | Direct | 92,211 |
Reported balance
After 2026-08-12 transaction · row 3
1 source rowRow 3 · 2026-08-12 · Sale · Disposed 11,048 · Balance 92,211 F5: The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC ("ABHMC") on March 31, 2026.
F2: The weighted average sale price for the transaction report was $26.07, and the range of prices were between $26.005 and $26.14, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3: ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
F4: The weighted average sale price for the transaction report was $26.23, and the range of prices were between $26.00 and $26.48, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F5: The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
TMC the metals Co Inc.
Report date September 09, 2021 · Filed September 10, 2021
Section 16 reporting ended · disclosed 2021-09-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 30,000 |
Reported balance
After 2021-09-09 transaction · row 1
1 source rowRow 1 · 2021-09-09 · Exercise / conversion · Acquired 30,000 · Balance 30,000 F1: On September 9, 2021, Sustainable Opportunities Acquisition Corp. (the former name of the Issuer), consummated its initial business combination (the "Business Combination") with DeepGreen Metals Inc. In connection with the Business Combination, each Class B ordinary share automatically converted into one common share on a one-for-one basis. |
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-09-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-09-09 · Exercise / conversion · Disposed 30,000 · Balance 0 F1: On September 9, 2021, Sustainable Opportunities Acquisition Corp. (the former name of the Issuer), consummated its initial business combination (the "Business Combination") with DeepGreen Metals Inc. In connection with the Business Combination, each Class B ordinary share automatically converted into one common share on a one-for-one basis. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 9, 2021, Sustainable Opportunities Acquisition Corp. (the former name of the Issuer), consummated its initial business combination (the "Business Combination") with DeepGreen Metals Inc. In connection with the Business Combination, each Class B ordinary share automatically converted into one common share on a one-for-one basis.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2026 Filed Aug 12, 2026 21:47 UTC | Immunome Inc. IMNM · Entity 4219 | SaleCommon Stock | 11,048 | $27.25 | $301,058.00 |
DisclosureSEC source: 0001808343-26-000010 · form4-08122026_090856.xml · nonDerivative · entry 3 Barchas Isaac · CIK 0001808343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,211 F5 · kind: The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2026. Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 21:47 UTC | Immunome Inc. IMNM · Entity 4219 | SaleCommon Stock | 62,291 | $26.23 | $1,633,892.93 |
DisclosureSEC source: 0001808343-26-000010 · form4-08122026_090856.xml · nonDerivative · entry 2 Barchas Isaac · CIK 0001808343 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC ("ABHMC") on March 31, 2026. F4 · price: The weighted average sale price for the transaction report was $26.23, and the range of prices were between $26.00 and $26.48, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · ownership.nature: ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 21:47 UTC | Immunome Inc. IMNM · Entity 4219 | SaleCommon Stock | 10,125 | $26.07 | $263,958.75 |
DisclosureSEC source: 0001808343-26-000010 · form4-08122026_090856.xml · nonDerivative · entry 1 Barchas Isaac · CIK 0001808343 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 62,291 F1 · kind: The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC ("ABHMC") on March 31, 2026. F2 · price: The weighted average sale price for the transaction report was $26.07, and the range of prices were between $26.005 and $26.14, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · ownership.nature: ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares. Read SEC document |
| August 07, 2026 Filed Aug 10, 2026 20:10 UTC | Immunome Inc. IMNM · Entity 4219 | SaleCommon Stock | 15,248 | $26.06 | $397,362.88 |
DisclosureSEC source: 0001808343-26-000009 · form4-08102026_040801.xml · nonDerivative · entry 2 Barchas Isaac · CIK 0001808343 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 72,416 F1 · kind: The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC ("ABHMC") on March 31, 2026. F4 · price: The weighted average sale price for the transaction report was $26.06, and the range of prices were between $26.00 and $26.25, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · ownership.nature: ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares. Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 20:10 UTC | Immunome Inc. IMNM · Entity 4219 | SaleCommon Stock | 20,840 | $26.06 | $543,090.40 |
DisclosureSEC source: 0001808343-26-000009 · form4-08102026_040801.xml · nonDerivative · entry 1 Barchas Isaac · CIK 0001808343 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 87,664 F1 · kind: The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC ("ABHMC") on March 31, 2026. F2 · price: The weighted average sale price for the transaction report was $26.06, and the range of prices were between $26.00 and $26.3318, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · ownership.nature: ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares. Read SEC document |
| July 07, 2026 Filed Jul 7, 2026 23:02 UTC | Immunome Inc. IMNM · Entity 4219 | SaleCommon Stock | 16,906 | $24.20 | $409,125.20 |
DisclosureSEC source: 0001808343-26-000007 · form4-07072026_110744.xml · nonDerivative · entry 2 Barchas Isaac · CIK 0001808343 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 108,504 F1 · kind: The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC ("ABHMC") on March 31, 2026. F4 · price: The weighted average sale price for the transaction report was $24.20, and the range of prices were between $24.00 and $24.58, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · ownership.nature: ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares. Read SEC document |
| July 06, 2026 Filed Jul 7, 2026 23:02 UTC | Immunome Inc. IMNM · Entity 4219 | SaleCommon Stock | 83,094 | $24.11 | $2,003,396.34 |
DisclosureSEC source: 0001808343-26-000007 · form4-07072026_110744.xml · nonDerivative · entry 1 Barchas Isaac · CIK 0001808343 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 125,410 F1 · kind: The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC ("ABHMC") on March 31, 2026. F2 · price: The weighted average sale price for the transaction report was $24.11, and the range of prices were between $24.00 and $24.29, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · ownership.nature: ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares. Read SEC document |
| July 02, 2026 Filed Jul 3, 2026 00:31 UTC | Immunome Inc. IMNM · Entity 4219 | SaleCommon Stock | 24,335 | $23.33 | $567,735.55 |
DisclosureSEC source: 0001808343-26-000005 · form4-07032026_120754.xml · nonDerivative · entry 3 Barchas Isaac · CIK 0001808343 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 208,504 F1 · kind: The reported sale of these shares occurred automatically pursuant to Rule 10b5-1 trading plans adopted by ABHMC II LLC ("ABHMC") and Arsenal Bridge Venture II-B LLC ("ABV II-B"), each on March 31, 2026. F8 · price: The weighted average sale price for the transaction report was $23.33, and the range of prices were between $23.03 and $23.67, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F7 · ownership.nature: ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares. Read SEC document |
| July 02, 2026 Filed Jul 3, 2026 00:31 UTC | Immunome Inc. IMNM · Entity 4219 | SaleCommon Stock | 75,665 | $22.35 | $1,691,112.75 |
DisclosureSEC source: 0001808343-26-000005 · form4-07032026_120754.xml · nonDerivative · entry 2 Barchas Isaac · CIK 0001808343 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 232,839 F1 · kind: The reported sale of these shares occurred automatically pursuant to Rule 10b5-1 trading plans adopted by ABHMC II LLC ("ABHMC") and Arsenal Bridge Venture II-B LLC ("ABV II-B"), each on March 31, 2026. F6 · price: The weighted average sale price for the transaction report was $22.35, and the range of prices were between $22.015 and $23.015, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F7 · ownership.nature: ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares. Read SEC document |
| June 30, 2026 Filed Jul 3, 2026 00:31 UTC | Immunome Inc. IMNM · Entity 4219 | SaleCommon Stock | 101,050 | $21.12 | $2,134,176.00 |
DisclosureSEC source: 0001808343-26-000005 · form4-07032026_120754.xml · nonDerivative · entry 1 Barchas Isaac · CIK 0001808343 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnotes Disclosed balance after: 308,504 F1 · kind: The reported sale of these shares occurred automatically pursuant to Rule 10b5-1 trading plans adopted by ABHMC II LLC ("ABHMC") and Arsenal Bridge Venture II-B LLC ("ABV II-B"), each on March 31, 2026. F2 · shares: The shares were sold as follows: 100,000 shares were sold by ABHMC and 1,050 shares were sold ABV II-B. F3 · price: The weighted average sale price for the transaction report was $21.12, and the range of prices were between $20.83 and $21.47, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F4 · ownership.nature: The shares of Issuer common stock held by the Reporting Person prior to the transaction reported herein reflect pro rata distributions in kind for no additional consideration, effected by each of Arsenal Bridge Venture II LLC ("ABV II") and ABV II-B to their respective members, including ABHMC, the managing member of ABV II and ABV II-B. The receipt of such shares by the Reporting Person constituted a change in form of ownership and, therefore, was not required to be reported pursuant to Section 16, including Rule 16a-13. Following this transaction, ABHMC owns the remaining 308,504 shares of Issuer common stock. F5 · ownership.nature: The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC and is a co-founder and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABV II-B. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 21:48 UTC | Immunome Inc. IMNM · Entity 4219 | GrantDirector Stock Option (right to buy) · Derivative | 9,897 | $0.00 Strike: $18.16 | $0.00 |
DisclosureSEC source: 0001808343-26-000002 · form4-06122026_090628.xml · derivative · entry 1 Barchas Isaac · CIK 0001808343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,897 Underlying: Common Stock · 9,897 shares Expires 2036-06-09 F1 · shares: Mr. Barchas has agreed to receive and hold for the benefit of Arsenal Bridge Ventures any securities granted to him for his service as a director on the Company's board of directors. As such, Mr. Barchas disclaims beneficial ownership of, and all right, title and interest in, the reported securities. F2 · derivative.exercise_date: The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to Mr. Barchas' continuous service with the Company on each respective vesting date. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 21:41 UTC | Immunome Inc. IMNM · Entity 4219 | SaleCommon Stock | 11,251 | $22.34 | $251,347.34 |
DisclosureSEC source: 0001808343-25-000004 · form4-12232025_091227.xml · nonDerivative · entry 2 Barchas Isaac · CIK 0001808343 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 2,031,181 F1 · kind: The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2024. F6 · shares: The shares were sold as follows: 6,851 shares were sold by ABV II and 4,400 shares were sold by ABV II-B. F7 · price: The weighted average sale price for the transaction report was $22.34, and the range of prices were between $22.31 and $22.38, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F8 · balance_after: Following this transaction, ABV II and ABV II-B own 1,238,282 shares of Issuer common stock and 792,899 shares of Issuer common stock, respectively. F5 · ownership.nature: Mr. Barchas is a co-founder and holder of a power of attorney with the ability to exercise voting and investment power over the shares held by ABV II and ABV II-B. Mr. Barchas disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Mr. Barchas is the beneficial owner of such shares. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 21:41 UTC | Immunome Inc. IMNM · Entity 4219 | SaleCommon Stock | 371,949 | $21.72 | $8,078,732.28 |
DisclosureSEC source: 0001808343-25-000004 · form4-12232025_091227.xml · nonDerivative · entry 1 Barchas Isaac · CIK 0001808343 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnotes Disclosed balance after: 2,042,432 F1 · kind: The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2024. F2 · shares: The shares were sold as follows: 226,480 shares were sold by Arsenal Bridge Venture II, LLC ("ABV II") and 145,469 shares were sold by Arsenal Bridge Venture II-B, LLC ("ABV II-B" and collectively with ABV II, the "ABV Entities"). F3 · price: The weighted average sale price for the transaction report was $21.72, and the range of prices were between $21.31 and $22.30, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F4 · balance_after: Following this transaction, ABV II and ABV II-B own 1,245,133 shares of Issuer common stock and 797,299 shares of Issuer common stock, respectively. F5 · ownership.nature: Mr. Barchas is a co-founder and holder of a power of attorney with the ability to exercise voting and investment power over the shares held by ABV II and ABV II-B. Mr. Barchas disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Mr. Barchas is the beneficial owner of such shares. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:54 UTC | Immunome Inc. IMNM · Entity 4219 | GrantDirector Stock Option (right to buy) · Derivative | 18,864 | $0.00 Strike: $9.57 | $0.00 |
DisclosureSEC source: 0001415889-25-016982 · form4-06122025_080607.xml · derivative · entry 1 Barchas Isaac · CIK 0001808343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,864 Underlying: Common Stock · 18,864 shares Expires 2035-06-09 F1 · derivative.exercise_date: The option vests in four quarterly installments, commencing from June 10, 2025 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date. Read SEC document |
| June 13, 2024 Filed Jun 19, 2024 00:48 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock option (right to buy) · Derivative | 11,333 | $0.00 Strike: $16.04 | $0.00 |
DisclosureSEC source: 0001415889-24-017516 · form4-06192024_120629.xml · derivative · entry 1 Barchas Isaac · CIK 0001808343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,333 Underlying: Common Stock · 11,333 shares Expires 2034-06-12 F1 · derivative.exercise_date: The options vest in 4 quarterly installments, commencing from June 13, 2024 until the one year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to continued service with the Company on each respective vesting date. Read SEC document |
| October 27, 2023 Filed Oct 31, 2023 22:35 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock option (right to buy) · Derivative | 41,538 | $0.00 Strike: $8.73 | $0.00 |
DisclosureSEC source: 0001209191-23-053984 · doc4.xml · derivative · entry 1 Barchas Isaac · CIK 0001808343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,538 Underlying: Common Stock · 41,538 shares Expires 2033-10-26 F1 · shares: Mr. Barchas waived the initial grant provided for under the Company's non-employee director compensation policy in effect on the date he joined the Company's board of directors pending the adoption of an amended and restated non-employee director compensation policy (the "New NED Compensation Policy"). On October 27, 2023, the compensation committee of the Company's board of directors adopted and approved the New NED Compensation Policy. The above reflects Mr. Barchas' initial grant under the New NED Compensation Policy. F2 · derivative.exercise_date: The options vest in 12 quarterly installments over three years, commencing on October 2, 2023 and continuing thereafter on the same day of each succeeding fiscal quarter, subject to continued service with the Company on each respective vesting date. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 23:37 UTC | TMC the metals Co Inc. TMC · Entity 4335 | Exercise / conversionClass B ordinary shares · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-047499 · ownership.xml · derivative · entry 2 Barchas Isaac · CIK 0001808343 · Former Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A ordinary shares · 30,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 9, 2021, Sustainable Opportunities Acquisition Corp. (the former name of the Issuer), consummated its initial business combination (the "Business Combination") with DeepGreen Metals Inc. In connection with the Business Combination, each Class B ordinary share automatically converted into one common share on a one-for-one basis. F1 · kind: On September 9, 2021, Sustainable Opportunities Acquisition Corp. (the former name of the Issuer), consummated its initial business combination (the "Business Combination") with DeepGreen Metals Inc. In connection with the Business Combination, each Class B ordinary share automatically converted into one common share on a one-for-one basis. F1 · derivative.exercise_date: On September 9, 2021, Sustainable Opportunities Acquisition Corp. (the former name of the Issuer), consummated its initial business combination (the "Business Combination") with DeepGreen Metals Inc. In connection with the Business Combination, each Class B ordinary share automatically converted into one common share on a one-for-one basis. F1 · derivative.expiration_date: On September 9, 2021, Sustainable Opportunities Acquisition Corp. (the former name of the Issuer), consummated its initial business combination (the "Business Combination") with DeepGreen Metals Inc. In connection with the Business Combination, each Class B ordinary share automatically converted into one common share on a one-for-one basis. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 23:37 UTC | TMC the metals Co Inc. TMC · Entity 4335 | Exercise / conversionCommon Shares | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-21-047499 · ownership.xml · nonDerivative · entry 1 Barchas Isaac · CIK 0001808343 · Former Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On September 9, 2021, Sustainable Opportunities Acquisition Corp. (the former name of the Issuer), consummated its initial business combination (the "Business Combination") with DeepGreen Metals Inc. In connection with the Business Combination, each Class B ordinary share automatically converted into one common share on a one-for-one basis. F1 · price: On September 9, 2021, Sustainable Opportunities Acquisition Corp. (the former name of the Issuer), consummated its initial business combination (the "Business Combination") with DeepGreen Metals Inc. In connection with the Business Combination, each Class B ordinary share automatically converted into one common share on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.